Skip to main content

Table 3 The somatostatin levels calculated in the different groups.

From: The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis

 

Group 1

Group 2

Group 1 vs. Group 2

No SOM treatment

Uninf.: 119.4 ± 11.99

Acute: 297.3 ± 37.24

p-value: 0.01**

Chronic: 206.1 ± 13.30

Uninf.: 119.4 ± 11.99

Chronic: 206.1 ± 13.30

p-value: 0.008**

Acute: 297.3 ± 37.24

Chronic: 206.1 ± 13.30

p-value: 0.06 (BL)

1 day SOM treatment

Acute: 240.3 ± 21.30

Uninf.: 131.6 ± 19.34

Chronic: 226.3 ± 5.41

p-value: 0.01**

Acute: 240.3 ± 21.30

Chronic: 226.3 ± 5.41

p-value: 0.71 (NS)

2 day SOM treatment

Uninf.: 136.9 ± 11.69

Acute: 234.2 ± 23.65

p-value: 0.008**

Acute (untreated): 297.3 ± 37.24

Acute (2d SOM): 234.2 ± 23.65

p-value: 0.28

Uninf.: 151.6 ± 41.45

Chronic: 247.9 ± 13.11

p-value: 0.11 (NS)

Chronic (untreated): 206.1 ± 13.30

Chronic (2d SOM): 247.9 ± 13.11

p-value: 0.06 (BL)

Uninf. (17 wks.): 136.9 ± 11.69

Uninf. (21 wks.): 151.6 ± 41.45

p-value: 0.9 (NS)

Acute: 234.2 ± 23.65

Chronic: 247.9 ± 13.11

p-value: 0.73 (NS)

  1. SOM: somatostatin; Uninf.: uninfected; Inf.: infected; Wks.: weeks;
  2. * Significant difference (p < 0.05); ** significant difference (p < 0.01); BL: borderline significant difference; NS: not significant difference